158 related articles for article (PubMed ID: 23149257)
1. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
[TBL] [Abstract][Full Text] [Related]
2. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
Kratz F; Ehling G; Kauffmann HM; Unger C
Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
[TBL] [Abstract][Full Text] [Related]
3. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
Kratz F
Expert Opin Investig Drugs; 2007 Jun; 16(6):855-66. PubMed ID: 17501697
[TBL] [Abstract][Full Text] [Related]
4. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Kratz F; Walker UA
Int J Cancer; 2007 Feb; 120(4):927-34. PubMed ID: 17131338
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy.
Boga C; Fiume L; Baglioni M; Bertucci C; Farina C; Kratz F; Manerba M; Naldi M; Di Stefano G
Eur J Pharm Sci; 2009 Oct; 38(3):262-9. PubMed ID: 19695327
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
[TBL] [Abstract][Full Text] [Related]
8. Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin.
Liu L; Zhang C; Li Z; Wang C; Bi J; Yin S; Wang Q; Yu R; Liu Y; Su Z
Mol Pharm; 2017 Nov; 14(11):3739-3749. PubMed ID: 28950700
[TBL] [Abstract][Full Text] [Related]
9. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
10. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
11. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
13. Aldoxorubicin for the treatment of soft tissue sarcoma.
Sachdev E; Sachdev D; Mita M
Expert Opin Investig Drugs; 2017 Oct; 26(10):1175-1179. PubMed ID: 28846045
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.
Kratz F; Fichtner I; Graeser R
Invest New Drugs; 2012 Aug; 30(4):1743-9. PubMed ID: 21590366
[No Abstract] [Full Text] [Related]
15. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
[TBL] [Abstract][Full Text] [Related]
16. Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity.
Dragojevic S; Ryu JS; Hall ME; Raucher D
Molecules; 2022 May; 27(11):. PubMed ID: 35684309
[TBL] [Abstract][Full Text] [Related]
17. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
Graeser R; Esser N; Unger H; Fichtner I; Zhu A; Unger C; Kratz F
Invest New Drugs; 2010 Feb; 28(1):14-9. PubMed ID: 19148580
[TBL] [Abstract][Full Text] [Related]
18.
Cornillie J; Wozniak A; Pokreisz P; Casazza A; Vreys L; Wellens J; Vanleeuw U; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
Mol Cancer Ther; 2017 Aug; 16(8):1566-1575. PubMed ID: 28566438
[TBL] [Abstract][Full Text] [Related]
19. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate.
Di Stefano G; Lanza M; Kratz F; Merina L; Fiume L
Eur J Pharm Sci; 2004 Dec; 23(4-5):393-7. PubMed ID: 15567293
[TBL] [Abstract][Full Text] [Related]
20. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
